“At the end of the day the metric of our success as a business is going to be the number and quality of new medicines that we get approved by the FDA and regulators in other markets,” Ramaswamy said in an interview. “Everything else is just the means to do that.”
Vivek Ramaswamy’s Enzyvant Asks FDA To Approve Treatment For Dying Babies
